Atezolizumab

ClinicalAugust 1, 2026

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

A phase II/III trial is evaluating the efficacy of atezolizumab combined with standard chemotherapy in advanced or metastatic neuroendocrine carcinomas originating outside the lung.

Sponsor company

Mechanism of action

Recent signals(9)

Phase I Trial of Atezolizumab with Chemo for Relapsed/Refractory DLBCL

Phase I/II Trial of Atezolizumab and Cabozantinib in Recurrent Glioblastoma

Phase I/II Trial of Iadademstat with Atezolizumab or Durvalumab in Extensive Stage Small Cell Lung Cancer

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

Phase I Study of RO7566802 in Combination with Atezolizumab for Solid Tumors

Phase III Trial of Atezolizumab Post-Surgery for Stage I NSCLC Shows Promise

Phase II Trial of Atezolizumab with Chemotherapy for Peritoneal Mesothelioma

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

Upcoming milestones

Related catalysts

Indications

Therapeutic areas

Get signals before the market moves